CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 19 enrolled
Drug / intervention
GnRH +2 moredrug
Likely dose
NAL-GLU GnRH antagonist 150 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00386022
NCT00386022Phase 3Unknown
CompareCT.gov

The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration

Massachusetts General Hospital·interventional·Posted Oct 11, 2006·Updated Apr 13, 2017

In Brief

A Phase 3 clinical trial evaluating GnRH, NAL-GLU GnRH antagonist, and 1 other intervention for Healthy. Targeting 19 participants across 1 site.

Detailed Summary

The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 3UnknownOverdue
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 11, 2006
Enrollment StartJan 1, 2002
Primary CompletionJan 1, 2012
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 10 yearsPosted 19.7 years ago

Interventions

GnRHdrug

GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol

NAL-GLU GnRH antagonistdrug

A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol

Estrogen patchdrug

transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study